Sentence examples for brain metastases at presentation from inspiring English sources

Study subjects with brain metastases at presentation were less likely to have SVID (44.0%) than were those without brain metastases (71.7%) (p<0.0001, Figure 2).

The primary outcome measure was the portion of study subjects with and without SVID of the brain who had evidence of brain metastases at the time of initial staging of their lung cancer.109 patients (20.8%) had evidence of brain metastases at presentation and 345 (66.0%) had evidence of SVID.

Only one patient was recorded as having had brain metastases at presentation (0.6%).

A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-therapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation.

Moreover, we have documented that, unlike SCLC where up to 40.4% patients with extensive disease develop brain metastases at 1 year in the absence of PCI, 8 brain metastases in EPSCC are rare (2.5% in our study) at presentation and on follow-up.

Eleven patients had progressing brain metastases and did not receive radiation (group A), 9 patients had progressing brain metastases and received radiation when starting osimertinib (group B), and 20 patients had stable brain metastases at the time of initiating osimertinib (group C).

Ten –15% of patients with lung cancer have brain metastases at diagnosis, and an additional 20% 25% develop brain metastases during their illness [4].

Age at diagnosis of brain metastases, interval to brain metastases, number of brain metastases at first GKS, and treatment for brain metastases were not associated with survival following brain metastases.

To note, 20 patients had asymptomatic brain metastases at baseline.

For patients admitted with brain metastases at the same time, or subsequent to admissions for other distant metastases, we used the term 'Later brain metastases'.

The mean total cost for BC patients with brain metastases was more than twice that of patients without brain metastases at 6 and 12 months.